HTHSCI 1DT3 Lecture Notes - Lecture 2: Headache, Common Cold, Mesenchymal Stem Cell
13 Aug 2020
School
Department
Course
Professor
Document Summary
Mod. 1-21 proof of concept clinical studies with new drugs for asthma and copd 4. Roflumilast and pde4i: however, except for tiotropium a lama, all other drugs seems to fail to alter natural history of copd. Do not affect natural history of copd, measured by annual rate of loss in fev1. Torch study show that ics do not significantly decrease mortality in patients and. Fluticasone increases the risk of pneumonia: understanding potential long-term impacts on function with tiotropium (uplift) study. No significant effect on annual rate of decline of fev1. In moderate copd, tiotropium showed a trend to reduce the rate of decline of post- bronchodilator fev1. Mod. 1-21 proof of concept clinical studies with new drugs for asthma and copd 5. Pde4 inactivates camp, which is a intracellular brake on inflammation. Hence, inhibiting pde4 will help to increase camp levels: cilomilast (gsk) Initial study was very encouraging, but benefits not as great in larger 6-months study.
